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Abstract
Significance: Detection and characterization of circulating tumor cells (CTCs), a key determi-
nant of metastasis, are critical for determining risk of disease progression, understanding
metastatic pathways, and facilitating early clinical intervention.
Aim: We aim to demonstrate label-free imaging of suspected melanoma CTCs.
Approach: We use a linear-array-based photoacoustic tomography system (LA-PAT) to detect
melanoma CTCs, quantify their contrast-to-noise ratios (CNRs), and measure their flow veloc-
ities in most of the superficial veins in humans.
Results: With LA-PAT, we successfully imaged suspected melanoma CTCs in patients in vivo,
with a CNR >9. CTCs were detected in 3 of 16 patients with stage III or IV melanoma. Among
the three CTC-positive patients, two had disease progression; among the 13 CTC-negative
patients, 4 showed disease progression.
Conclusions:We suggest that LA-PAT can detect suspected melanoma CTCs in patients in vivo
and has potential clinical applications for disease monitoring in melanoma.
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1 Introduction
More than 90% of cancer-associated mortality is caused by metastasis,1 the process of cancer
cells spreading from a primary tumor site to surrounding tissues and distant organs to form new
tumors. During the entire metastatic process, a cancer cell executes multiple steps, including
acquiring an invasive phenotype, invading the surrounding tissue, entering the local blood or
lymphatic vessel (intravasation), surviving and circulating in the blood stream, exiting through
vessels to distant tissues (extravasation), adapting to the new microenvironment, and growing
into metastases.2 In this complicated metastatic cascade, the rare circulating tumor cells (CTCs)
are key determinants of metastatic propensity.3,4 Considered as “seeds” of metastases, the
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presence and concentration of CTCs are closely correlated with tumor progression, metastases,
and survival rates in patients.5 Thus, efficient detection and characterization of CTCs will make
critical contributions to cancer diagnosis and staging, therapy response assessment, and residual
disease evaluation after surgery.
Recent advances in biomedical techniques have enabled intensive studies of CTCs in the
bloodstream,6 typically utilizing tumor-specific physical and biological properties to detect,
capture, or isolate CTCs. However, these methods have certain limitations. Most ex vivo
CTC detection assays, including the CTC microchip and the FDA-approved CellSearch
(CELLSEARCH®), rely on epithelial markers.7,8 A subpopulation of CTCs could be missed
in such assays because some CTCs can shield their epithelial markers or express fewer markers
after transition. A new generation of microchip was developed to isolate CTC clusters based on
size.9 However, it is constrained by the limited blood sample volume in ex vivo assays relative to
the patient’s entire blood volume, which reduces the sensitivity of CTC detection. To improve
the detection sensitivity, in vivo optical CTC imaging techniques have also been developed,10
including in vivo fluorescent flow cytometry,11 in vivo photoacoustic flow cytometry,12 and mul-
tiphoton microscopy.13 However, most of these techniques require labeling CTCs by transfec-
tion, and their clinical translation is impeded by low in vivo transfection efficiency as well as the
potential toxicity of labeled CTCs. Furthermore, because of strong optical scattering in biologi-
cal tissue, prior noninvasive optical CTC imaging methods rely on imaging special anatomical
sites, such as the mouse ear.12 Sites with similar optical properties may not be readily available
for human studies. Even if these techniques can be applied to detect CTCs at a favorable ana-
tomical site, these methods may be incapable of monitoring early metastasis away from this
site.14 Therefore, a new imaging method that can monitor metastasis using endogenous contrast
over a long duration at an arbitrary anatomical location is desirable.
By ultrasonically imaging optical absorption contrast, photoacoustic tomography (PAT)
achieves label-free imaging of biological tissue in vivo beyond the optical diffusion limit for
tissue penetration and provides new opportunities for CTC imaging. The weak ultrasonic scat-
tering in soft tissue allows PAT to access large blood vessels with high flow rates at depths,
achieving a higher throughput for CTC detection than pure optical techniques. In this work,
we focus on CTC detection in melanoma, the most fatal type of skin cancer, with more than
87,000 new diagnoses and 10,000 deaths each year.15 Melanoma has a high tendency to meta-
stasize, after which the 5-year survival rate decreases from 98.5% to <20%. Effective detection of
CTCs is critical for determining the risk of disease progression, understanding metastatic path-
ways, and facilitating early and effective clinical intervention. PAT is particularly suitable for
melanoma CTC detection owing to the strong optical absorption of the highly expressed mela-
nin, which serves as an intrinsic contrast.16
Herein, we describe the development of a PAT system based on a linear ultrasonic transducer
array (LA-PAT) and present label-free high-throughput imaging of suspected melanoma CTCs,
in humans in vivo for the first time. We initially imaged flowing melanoma tumor cells in micro-
tubes in vitro to demonstrate the capability of LA-PAT. Then, we imaged 16 stage III and IV
melanoma patients with LA-PAT and successfully detected suspected melanoma CTCs in three
patients. The imaging results of suspected melanoma CTCs were validated with contrast-to-noise
ratio (CNR) analysis among healthy volunteers, CTC-negative patients, and CTC-positive
patients. The clinical relevance of suspected CTC detection was studied by follow-up monitoring
of the patients imaged.
2 Methods
2.1 Determining the Optimal Excitation Wavelength for Photoacoustic
Imaging of Circulating Melanoma Tumor Cells
Achieving the highest detection sensitivity of melanoma CTCs in blood requires choosing an
excitation wavelength that maximizes the contrast between melanoma CTCs (the target) and
blood (the background). We compared the optical absorption spectra of melanoma tumor cells
(assuming an average 43% volume fraction of melanosome, as found in typical darkly pigmented
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skin cells),17,18 and red blood cells (RBCs) in venous blood (assuming 85% oxygen saturation19)
in Fig. S1(A) in the Supplemental Materials. Based on the absorption spectra, we calculated the
optical absorption coefficient ratio of melanoma tumor cells to RBCs in venous blood to select
the wavelength that maximizes the contrast. Venous blood was used as the background here
because veins, at shallow depths in tissue and with large blood volumes, are ideal imaging targets
for detecting suspected melanoma CTCs in patients. Based on the optical absorption coefficient
ratio, an excitation wavelength of 680 nm was chosen to maximize the contrast between
melanoma CTCs and blood and achieve the highest detection sensitivity [Fig. S1(B) in the
Supplemental Materials].
An excitation wavelength of 680 nm not only maximizes the photoacoustic signal ratio of a
melanoma CTC to an RBC but also allows sufficient light penetration in biological tissue to
access large blood vessels at depths. However, locating blood vessels in patients may be difficult,
given the weak optical absorption of hemoglobin at 680 nm. This minor drawback was overcome
using an excitation wavelength of 850 nm to locate the blood vessels prior to switching to
680 nm for melanoma CTC imaging. The 40-MHz center frequency of the ultrasonic transducer
array was chosen in order to provide sufficient sensitivity to detect single melanoma CTCs while
ensuring that the imaging depth was adequate to screen large blood vessels for high-throughput
CTC imaging. A lower ultrasonic frequency, such as 21 MHz, can yield deeper penetration in
biological tissue.20 However, a 21-MHz transducer array has only ∼45% CTC detection sensi-
tivity in comparison with the 40-MHz transducer array at the same depths, because the number of
RBCs in one resolution voxel is increased by a factor of ∼5. A higher ultrasonic frequency,
however, such as 50 MHz, can achieve an even higher melanoma CTC detection sensitivity,
but suffers from stronger acoustic attenuation and the inability to reach the deep target vessels
for high-throughput melanoma CTC imaging. Therefore, an illumination wavelength of 680 nm
and a detection center frequency of 40 MHz represent the most efficacious combination to enable
label-free high-throughput melanoma CTC imaging in patients in vivo.
2.2 Linear-Array-Based Photoacoustic Tomography System for Imaging
Circulating Melanoma Tumor Cells
To achieve label-free high-throughput imaging of melanoma CTCs, we upgraded a PAT system
(Visualsonics Inc., Vevo LAZR) based on an LA-PAT [Fig. S5 in the Supplemental Materials).
After careful analysis, an excitation wavelength of 680 nm was chosen to maximize the contrast
between melanoma CTCs and blood [Fig. S1(B) in the Supplemental Materials] and another
excitation wavelength of 850 nm was chosen to locate blood vessels in melanoma patients. To
provide excitation wavelengths of 680 and 850 nm, a tunable optical parametric oscillator laser
(680 to 970 nm, 20-Hz pulse repetition rate) was used, and the excitation wavelength could be
manually switched. To ensure the safety of patients, the laser beam was coupled into an optical
fiber bundle. The optical fiber bundle bifurcated, and laser beams coming out of the optical
fiber bundles illuminated the imaging area at a 30-deg angle of incidence to the imaging plane.
The fluence on the tissue surface during the experiments was ∼11 mJ∕cm2, well within the
20 mJ∕cm2 safety limit set by the American National Standards Institute.21 The generated
photoacoustic waves were detected by a linear array ultrasonic transducer (Visualsonics,
Inc., MS550D, 40-MHz center frequency, 33-MHz bandwidth, and 256 elements). Four-to-one
multiplexing was used in image acquisition because there were 256 elements in the linear array
transducer and 64 channels in the data acquisition unit. In detail, for each laser pulse, the gen-
erated photoacoustic signals were captured sequentially by a quarter segment of the linear array
(i.e., elements 1 to 64, 65 to 128, 129 to 192, and 193 to 256). A two-dimensional photoacoustic
image was reconstructed with the universal backprojection algorithm after the data were
acquired from all four quarter segments. The linear array ultrasonic transducer was connected
to the imaging platform, where the reconstructed photoacoustic images were displayed. The
imaging frame rate was 5 frames∕s, determined jointly by the 20-Hz laser repetition rate and
four-to-one multiplexing in image acquisition. The frame rate could be adjusted by utilizing
fewer elements in the linear array transducer, at the expense of a smaller imaging field of
view (FoV).
Hai et al.: Label-free high-throughput photoacoustic tomography of suspected circulating melanoma. . .
Journal of Biomedical Optics 036002-3 March 2020 • Vol. 25(3)
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 16 Mar 2020
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
2.3 Detection Sensitivity of the LA-PAT System
The detection sensitivity of LA-PAT ultimately depends on the CNR, which allows visualizing a
melanoma CTC against the background of RBCs. The CNR can be expressed by the following
equation when the fluctuation of the number of RBCs in each resolution voxel is the dominant
noise (Note S1 in the Supplemental Materials):
EQ-TARGET;temp:intralink-;e001;116;668CNR ¼
PACTC
PARBCﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ½RBCwo
p : (1)
Here, PACTC and PARBC stand for the average photoacoustic signals of a melanoma CTC and an
RBC, and ½RBCwo represents the average number of RBCs in a resolution voxel without cir-
culating cells containing melanin. The photoacoustic signal ratio of a melanoma CTC and an
RBC, at the same optical fluence, is determined by the absorption coefficient ratio and the cell
volume ratio. The absorption coefficient ratio can be maximized by optimizing the illumination
wavelength. The average number of RBCs in each resolution voxel is determined by the RBC
number density and the resolution voxel size, which is affected by the ultrasonic transducer
frequency.
2.4 Spatial Resolutions of the LA-PAT System
The spatial resolutions of the LA-PAT system were quantified by imaging a carbon fiber with a
diameter of 6 μm. First, the carbon fiber was placed perpendicular to the imaging plane, and a
cross section image of the carbon fiber was acquired by LA-PAT [Fig. S6(A) in the Supplemental
Materials]. The photoacoustic amplitude profile of the carbon fiber along the axial direction was
fitted to a Gaussian function, and the axial resolution of the LA-PAT system, measured as the
full-width at half-maximum, was quantified to be 43 μm [Fig. S6(B) in the Supplemental
Materials]. The LA-PAT system was then scanned along the elevational direction with a step
size of 20 μm. To quantify the lateral resolution, a maximum amplitude projection (MAP) image
was obtained along the axial direction of the carbon fiber [Fig. S6(C) in the Supplemental
Materials]. Similarly, the photoacoustic amplitude profile of the carbon fiber along the lateral
direction was fitted to a Gaussian function, and the lateral resolution of the LA-PAT system was
quantified to be 94 μm [Fig. S6(D) in the Supplemental Materials]. To quantify the elevation
resolution, the carbon fiber was placed along the lateral direction of the LA-PAT system. The
LA-PAT system was then scanned along the elevational direction with a step size of 20 μm,
and an MAP image along the axial direction of the carbon fiber was obtained [Fig. S6(E) in
the Supplemental Materials]. The photoacoustic amplitude profile of the carbon fiber along
the elevational direction was fitted to a Gaussian function, and the elevational resolution of the
LA-PAT system was quantified to be 633 μm [Fig. S6(F) in the Supplemental Materials].
2.5 Cell Culture
AB16 mouse melanoma cell line was obtained from the Tissue Culture and Support Center at the
Washington University School of Medicine. The B16 cells were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen), supplemented with 10% fetal bovine serum (Gibco), at 37°C in
5% CO2. At 75% to 80% confluence, cells were harvested with 0.25% trypsin-EDTA solution
(Gibco).
2.6 Phantom Preparation
To mimic blood vessels of different diameters, silicone microtubes (Dow Corning) with inner
diameters of 0.3, 0.5, 0.64, 0.76, 1, 1.5, 2, 2.64, and 3.35 mm were perfused with bovine blood
(905, Quad-Five). The microtubes were embedded at different depths in tissue-mimicking gel-
atin phantoms (10% gelatin, G2500, Sigma-Aldrich, Inc.). To achieve optical scattering similar
to that in biological tissue, 1% intralipid was added to the gelatin phantoms. The acoustic proper-
ties of tissue-mimicking phantoms have been reported.22 Melanoma tumor cells suspended in
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bovine blood were pumped through the microtubes with a syringe. A syringe pump (BSP-99M,
Braintree Scientific) controlled the blood flow speed.
2.7 Detection Efficiency Calculation
To quantify the melanoma tumor cell detection efficiency of LA-PAT, ∼1000 single melanoma
tumor cells were suspended in 10-mL bovine blood and pumped through a microtube with
a syringe. The melanoma tumor cells and blood were collected at the other end of the microtube.
After ∼50 melanoma tumor cells had been captured by LA-PAT, the collected melanoma tumor
cells and blood mixture were examined with an optical microscope to count the number of mela-
noma tumor cells pumped through the microtube. The detection efficiency E is defined as
EQ-TARGET;temp:intralink-;e002;116;603 ¼ n
N
: (2)
Here, n stands for the number of melanoma tumor cells captured by LA-PAT, and N stands for
the number of melanoma tumor cells counted by optical microscopy.
2.8 Imaging Procedure for Melanoma Patients
This protocol was approved by the Institutional Review Board of Washington University in
St. Louis (IRB #201410125), and the study was part of a larger clinical trial (Clinical registra-
tion: Clinicaltrials.gov NCT02613325). In this trial, the primary purpose was to use a PAT
system to determine melanoma depth in the skin, and the secondary purpose was to assess the
feasibility and functionality of a PAT system in the detection of suspected CTCs. A total of
24 subjects were enrolled in this trial, and of the 16 patients described in the current study
(Table S2 in the Supplemental Materials), three patients met inclusion criteria for both primary
and secondary outcomes. Results for the primary outcome have been previously published.23
For this study, after informed consent was obtained, the patients were seated in a large chair
or were lain on a portable patient bed. Depending on the location of the melanoma or known
metastases, either the cephalic veins or the saphenous veins were imaged—the vessel proximal to
the melanoma tumor site was chosen for imaging. First, an excitation wavelength of 850 nm was
used to locate the melanoma and then its proximate vein (Fig. S7 in the Supplemental Materials).
Second, we moved the linear array ultrasonic transducer downstream until we found the most
superficial section of the vein in the patient’s forearm or leg. Finally, we kept the linear array
ultrasonic transducer at this location and switched to 680 nm to detect melanoma CTCs. Each
patient was usually imaged for 20 min, and during the entire imaging session, laser safety glasses
with an optical density >5 at 680 and 850 nm were worn to ensure the safety of the patient and
operator.
2.9 Flow Speed of Suspected Melanoma Tumor Cells
To make robust measurements of the flow speed of suspected melanoma tumor cells, we con-
verted their motion images to the space–time domain. The time traces of each pixel along the
yellow dashed line in Figs. S2(A) and S2(B) in the Supplemental Materials were extracted, and
the signals were shown as an image in the space–time domain (Fig. S2 in the Supplemental
Materials). After the data were fitted to a linear function, the slope of the linear function in the
space–time domain was used to calculate the speed of the melanoma CTCs.
3 Results
3.1 LA-PAT of Melanoma Tumor Cells in Phantoms
To initially demonstrate the capability of LA-PAT, we first applied it to image melanoma tumor
cells in tissue-mimicking phantoms. An excitation wavelength of 680 nm was used, which maxi-
mized the contrast between melanoma tumor cells and blood (Fig. S1 in the Supplemental
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Materials). Due to the strong optical absorption of melanin at 680 nm, the flowing melanoma
tumor cells emitted much stronger photoacoustic signals than the blood in the background and
were detected by LA-PAT [Figs. 1(a) and 2(a)].
The ability to detect and visualize melanoma tumor cells in the bloodstream depends on the
CNR (Note S1 in the Supplemental Materials). To determine the maximum depth at which mela-
noma tumor cells could be detected by LA-PAT, we studied how the imaging depth affected the
CNR. Microtubes mimicking blood vessels were embedded in scattering gelatin phantoms at
different depths, and melanoma tumor cells suspended in blood were pumped through the micro-
tubes. We used LA-PAT to image the flowing melanoma tumor cells [Figs. 1(a)–1(d), 2(b), and
2(c)] and calculated the CNR at each depth [Fig. 1(e)]. The CNR decreases with the increasing
imaging depth because both the optical fluence and the acoustic signal attenuate. With a CNR
threshold of 2, the maximum depth at which a melanoma tumor cell could be detected by LA-
PAT with a confidence level of 94.5% was ∼3.5 mm. This depth is adequate for imaging most
superficial veins in humans.
We also studied the melanoma tumor cell detection efficiency of LA-PAT. Despite high detec-
tion sensitivity, there are two situations where LA-PAT could miss a melanoma tumor cell.
50
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Fig. 1 LA-PAT of single melanoma tumor cells in phantom. (a) Photoacoustic snapshots of a
single melanoma tumor cell in a transparent phantom with a CNR of 16.4. The yellow arrows show
the microtube boundaries. The red arrows highlight the circulating single melanoma tumor cell
[Video 1(a)]. (b) Photoacoustic snapshots of a single melanoma tumor cell 1.5 mm deep in a scat-
tering phantom with a CNR of 14.2 [Video 1(b)]. (c) Photoacoustic snapshots of a single melanoma
tumor cell 3 mm deep in a scattering phantom with a CNR of 4.3 [Video 1(c)]. (d) Photoacoustic
snapshots of the scattering phantom at a depth of 4 mm. No melanoma tumor cells are visible.
(e) CNRs of the melanoma tumor cells in photoacoustic images degrade with increasing imaging
depth. With a CNR threshold of 2, the maximum depth at which a melanoma tumor cell could be
detected was ∼3.5 mm. (f) The melanoma tumor cell detection efficiency of LA-PAT decreases
with increasing blood flow speed and vessel diameter.
Hai et al.: Label-free high-throughput photoacoustic tomography of suspected circulating melanoma. . .
Journal of Biomedical Optics 036002-6 March 2020 • Vol. 25(3)
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics on 16 Mar 2020
Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
First, a melanoma tumor cell could flow outside of FoV, as when the diameter of the blood vessel
is larger than the slice thickness of the ultrasonic detection, i.e., the elevational resolution.
Second, a melanoma tumor cell could flow too quickly through the FoV. To quantify the detec-
tion efficiency, we imaged melanoma tumor cells at different flow speeds in microtubes with
different diameters and calculated the detection efficiencies for different parameter combinations
[Fig. 1(f)]. Detection efficiency decreases with increasing blood flow speed and vessel diameter.
These detection efficiency curves may serve as a reference for estimating the total number of
melanoma CTCs from the number detected by LA-PAT.
3.2 LA-PAT of a Single Suspected Melanoma CTC and a Suspected
Melanoma CTC Cluster in Patient 1
The first positive patient (M3) had stage IIIB recurrent metastatic melanoma with multiple
in-transit metastases of the right lower extremity (Table S1 in the Supplemental Materials).
The small saphenous vein of the right leg, with a diameter of ∼1.7 mm, was imaged. The vein
measured ∼3.1 mm from the skin surface to the deep vessel boundary. In the photoacoustic
Fig. 2 LA-PAT of flowing single melanoma tumor cells at different depth in phantoms (Video 1,
MP4, 1.1 KB [URL: https://doi.org/10.1117/1.JBO.25.3.036002.1]).
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images, structures including skin, vessel boundaries, and subcutaneous fat were clearly resolved
[Fig. 3(a)].
In one 7-min imaging session, LA-PAT detected a single melanoma CTC in this patient. The
single cell, with a CNR of ∼12.6, was captured at five instants during its passage through the
entire FoV [Fig. 3(a)]. Differential photoacoustic images were obtained [Fig. 3(b)], then super-
imposed on the structural images to better illustrate how the cell traversed the entire FoV
[Figs. 3(c) and 4(a)]. Pixelwise subtraction of one frame from the next frame generated a differ-
ential image. A global threshold was applied to differential images, with a threshold level set at
two times the noise level, estimated as the standard deviation of the background signal outside
the imaged region. The flow speed of the CTC was computed to be ∼10.3 mm∕s by analyzing its
movement in the space–time domain (Fig. S2 in the Supplemental Materials). Although the flow
speed does not exactly match the flow speed of blood, it is a close approximation.
In another 7-min imaging session with this patient, LA-PAT detected a CTC cluster. The
cluster, with a CNR of ∼11.6, was captured at nine instants as it traversed the entire imaging
FoV [Fig. 5(a)]. It was captured more often than the single cell because of its lower flow speed.
As before, differential photoacoustic images were obtained [Fig. 5(b)] and superimposed on the
structural images to illustrate the passage through the entire FoV [Figs. 4(b) and 5(c)]. Applying
the same method as for the single cell, the flow speed of the cluster was computed to be
∼5.4 mm∕s (Fig. S2 in the Supplemental Materials). A possible explanation for the lower flow
speed of the cluster compared to the single CTC is that the cluster was closer to the vessel boun-
dary, while the single cell was situated closer to the vessel centerline. Assuming a parabolic flow,
the flow speed near the centerline would be greater than that near the vessel boundary.
3.3 LA-PAT of a Single Suspected Melanoma CTC in Patient 2
The second positive patient (M11) had stage IV metastatic melanoma (Table S1 in the
Supplemental Materials). The cephalic vein of the right forearm, with a diameter of ∼10 mm,
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Fig. 3 LA-PAT of a single suspected melanoma CTC in patient 1. (a) Photoacoustic snapshots
of the melanoma CTC in the patient. The yellow arrows indicate structures, including the skin,
vessel boundaries, and subcutaneous fat layer. The red arrows highlight the melanoma CTC.
(b) Differential photoacoustic images showing only the melanoma CTC. (c) Differential photo-
acoustic images (b) superimposed on structural photoacoustic images (a), highlighting the
melanoma CTC [Video 2(a)].
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was imaged. The vein measured ∼3.2 mm from the skin surface to the deep vessel boundary
[Fig. 6(a)].
In one 7-min imaging session, LA-PAT detected a single melanoma CTC in this patient, with
a CNR of ∼9.4. The single cell was captured at five instants during its traverse of the entire FoV
[Fig. 6(a)]. As before, differential photoacoustic images were obtained [Fig. 6(b)] and then
Fig. 4 LA-PAT of melanoma CTCs in patients (Video 2, MP4, 1.5 KB [URL: https://doi.org/10
.1117/1.JBO.25.3.036002.2]).
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Fig. 5 LA-PAT of a suspected melanoma CTC cluster in patient 1. (a) Photoacoustic snapshots of
the melanoma CTC cluster in the patient. The yellow arrows indicate structures, including the
skin, vessel boundaries, and subcutaneous fat layer. The red arrows highlight the melanoma
CTC cluster. (b) Differential photoacoustic images showing only the melanoma CTC cluster.
(c) Differential photoacoustic images (b) superimposed on structural photoacoustic images (a),
highlighting the melanoma CTC cluster [Video 2(b)].
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superimposed on the structural images to illustrate how the melanoma CTC traversed the entire
FoV [Figs. 4(c) and 6(c)]. Per previous calculations, by converting the movement of the single
cell to the space–time domain, the flow speed of the melanoma CTC was estimated to
be ∼9.6 mm∕s.
3.4 LA-PAT of a Suspected Melanoma CTC Cluster in Patient 3
The third positive patient (M14) had stage IIIC metastatic melanoma with both in transit
metastasis and nodal disease (Table S1 in the Supplemental Materials). The cephalic vein of
the patient’s right forearm, with a diameter of ∼10 mm, was imaged. The vein measured
∼2.2 mm from the skin surface to the deep vessel boundary. In the photoacoustic images, struc-
tures, including the skin and vessel boundaries, were clearly resolved [Fig. 7(a)].
In one 7-min imaging session, LA-PAT detected a melanoma CTC cluster in this patient. The
CNR of the melanoma CTC cluster was ∼12.5. The melanoma CTC cluster was captured at three
instants as it traversed the entire FoV [Fig. 7(a)]. Again, to highlight the circulating melanoma
CTC, differential photoacoustic images were obtained [Fig. 7(b)]. The differential photoacoustic
images were then superimposed on the structural images to better illustrate how the melanoma
CTC cluster traversed the entire FoV [Figs. 4(d) and 7(c)]. The flow speed of the melanoma CTC
cluster was estimated to be ∼8.6 mm∕s.
3.5 CNR Analysis of Suspected Melanoma CTCs
To confirm that the high-CNR circulating entities detected by LA-PAT were attributed to cells
containing a large amount of melanin, we performed a thorough CNR analysis in tissue phan-
toms and patients. In phantoms, blood without melanoma tumor cells was pumped through the
microtube at a constant speed and imaged by LA-PAT. Considering the spatial resolution of
LA-PAT, we segmented the microtube into multiple regions and defined each region as an entity.
Fig. 6 LA-PAT of a single suspected melanoma CTC in patient 2. (a) Photoacoustic snapshots
of the melanoma CTC in the patient. The yellow arrows indicate structures, including the skin,
vessel boundaries, and subcutaneous fat layer. The red arrows highlight the melanoma CTC.
(b) Differential photoacoustic images showing only the melanoma CTC. (c) Differential photo-
acoustic images (b) superimposed on structural photoacoustic images (a), highlighting the
melanoma CTC [Video 2(c)].
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The location of one entity in the next frame was calculated from the flow speed of blood and the
frame rate of LA-PAT. As expected, no flowing entities with a CNR averaged over sequential
frames above 2.0 were detected in the photoacoustic images [Fig. S3(A) in the Supplemental
Materials]. We then searched within the microtube to find the static pixel with the highest CNR,
referred as the peak CNR. Next, pigmented B16 murine melanoma cells were suspended in
blood and pumped through the microtube. LA-PAT detected high-CNR flowing entities with
CNRs greater than 2.0 in the photoacoustic images [Fig. S3(B) in the Supplemental Materials].
The CNRs of the high-CNR entities with melanoma tumor cells were higher than the peak CNR
of blood by a factor of ∼3.5 [Fig. S3(C) in the Supplemental Materials]. Because the added
melanoma tumor cells were the only difference from the control experiment, the high-CNR flow-
ing entities were identified as melanoma tumor cells. At an excitation wavelength of 680 nm,
only a melanin-containing cell that is much more absorbing than an RBC in blood (Fig. S1 in the
Supplemental Materials, and Sec. 2) could generate such strong photoacoustic signals (Note S1
in the Supplemental Materials). In addition, the average CNR of the flowing entities with
melanoma cells was ∼14.7, close to the theoretically estimated value of 15 (Note S1 in the
Supplemental Materials).
To further validate the identification of the high-CNR circulating entities in vivo as cells
containing melanin, we similarly analyzed the CNRs in patients, with several control groups.
First, we calculated the average CNR of each circulating entity in the photoacoustic images
[Fig. S4(A) in the Supplemental Materials]. For the initial control, we compared the CNRs
of the circulating entities with the peak background CNRs in the blood vessels of patients in
whom high-CNR circulating entities were detected, referred to as CTC-positive patients. In
frames without high-CNR circulating entities, we scanned the entire area within the blood vessel
and found the pixel with the highest CNR [Fig. S4(B) in the Supplemental Materials]. In the
blood vessels of CTC-positive patients, the CNRs of the high-CNR circulating entities were
higher than the peak background CNRs by a factor of ∼2.7 [Fig. S4(E) in the Supplemental
Materials]. For the second control, we compared the CNRs of the high-CNR circulating entities
with the peak CNRs in the blood vessels of patients in whom no high-CNR circulating entities
were detected, referred to as CTC-negative patients. Similarly, we scanned the entire area within
the blood vessel and found the pixel with the highest CNR [Fig. S4(C) in the Supplemental
Materials]. The CNRs of the high-CNR circulating entities were also higher than the peak back-
ground CNRs in the blood vessels of CTC-negative patients, by a factor of ∼2.8 [Fig. S4(E) in
the Supplemental Materials]. For the third control, we compared the CNRs of the high-CNR
circulating entities with the peak background CNRs in the blood vessels of healthy volunteers
[Fig. S4(D) in the Supplemental Materials]. Consistent with the first two controls, CNRs of the
CTC cluster
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Fig. 7 LA-PAT of a suspected melanoma CTC cluster in patient 3. (a) Photoacoustic snapshots of
the melanoma CTC cluster in the patient. The yellow arrows indicate structures, including the skin
and vessel boundaries. The red arrows highlight the melanoma CTC cluster. (b) Differential photo-
acoustic images showing only the melanoma CTC cluster. (c) Differential photoacoustic images
(b) superimposed on structural photoacoustic images (a), highlighting the melanoma CTC cluster
[Video 2(d)].
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high-CNR circulating entities in melanoma patients were higher than the peak CNRs measured
in blood vessels of healthy volunteers, by a factor of ∼2.4 [Fig. S4(E) in the Supplemental
Materials]. Taken together, this analysis supports the assertion that the circulating entities with
high photoacoustic signals detected by LA-PAT in the three patients correspond to circulating
cells containing melanin.
3.6 Estimation of the Total Number of CTCs and the Clinical Relevance of
CTC Imaging in Patients
To show the potential of LA-PAT melanoma CTC imaging for analysis of metastasis, we then
monitored their clinical courses for several months following photoacoustic imaging. Based on
the detected numbers of suspected melanoma CTCs and the effective blood volumes screened by
LA-PAT, our results were consistent with the numbers reported previously using ex vivo CTC
detection methods24,25 (Table S1 in the Supplemental Materials). We wanted to determine
whether the detection of suspected CTCs was predictive of patient response to treatment
and/or disease progression.26 The data were deidentified, the results were not shared with
patients or their treating physicians, and the results did not affect any clinical treatment decisions.
In our study, two of the three CTC-positive patients (M3 and M11) had disease progression
despite being on systemic therapy, and patient M11 ultimately died from his disease. One
CTC-positive patient (M12) demonstrated no disease progression off therapy. This case may
not be associated with a false-positive test result because the presence of CTCs may not always
lead to disease progression. In contrast, only 4 of 13 CTC-negative patients had disease pro-
gression that may indicate false-negative results (Fig. 8).
4 Discussion
PAT, which is based on ultrasonically imaging optical absorption, is inherently suitable for mela-
noma imaging and offers four advantages. (1) PAT has a 100% relative sensitivity to optical
absorption (i.e., a given small percentage change in the optical absorption coefficient yields the
same percentage change in the photoacoustic amplitude), thus allowing high-sensitivity detec-
tion of strongly absorbing targets;27 (2) most melanoma tumor cells express high-concentration
Fig. 8 Follow-up of melanoma patients after being imaged by LA-PAT. Among three patients with
detected suspected CTCs, two demonstrated disease progression on therapy, while one had
no disease progression off therapy. Among 13 patients without CTCs detected, 4 demonstrated
disease progression. See text for further details.
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melanin, which has much stronger optical absorption than hemoglobin in the red to near-infrared
spectral range and serves as an intrinsic contrast for high-sensitivity photoacoustic detection of
melanoma CTCs in the bloodstream; (3) taking advantage of the ultrasonic transparency of bio-
logical tissue, PATachieves high resolution at depths, enabling assessment of large blood vessels
for high-throughput screening of melanoma CTCs; (4) LA-PAT, the linear-array-based imple-
mentation of PAT, optimally aligns the FoV with the blood vessel, which maximizes the blood
imaging efficiency (i.e., the ratio of the volume of blood examined to the entire tissue volume
imaged by LA-PAT) and increases the likelihood of melanoma CTCs detection in patients.
Capitalizing on these advantages, we successfully achieved label-free high-throughput imaging
of suspected melanoma CTCs in patients in vivo.
Melanoma CTC detection has been studied with multiple ex vivo modalities that utilize
melanocyte-specific proteins and RNA sequences thought to be upregulated in melanoma cells.
These modalities have been studied in patients with stage I through IV melanoma, and there is
significant variation in the percentage of patients found to have CTCs and the number of CTCs
detected, with estimates ranging from 13% to 80% of melanoma patients having detected
CTCs.24 Some of the higher estimates may be the result of repeat sampling of the same patient
over a study’s duration, as well as inclusion of multiple melanocyte markers. Some of the lower
estimates may reflect the result of inclusion of Stage I and II patients.
Given that our study was limited to stages III and IV patients, a relevant comparable study
is by Khoja et al., who reported detection of CTCs in 40% of 101 patients with stage IV
melanoma.28 These patients were examined for the presence of CTCs multiple times during
the study, and a melanoma-specific commercially available ex vivo CellSearch system utilizing
three markers (MelCAM, melanoma-associated chondroitin sulphate proteoglycan, and CD45)
was used. The number of cells detected in a 7.5-ml sample of blood for the patients with detected
CTCs was 0.133 CTCs∕ml for 35% of patients, 0.267 CTCs∕ml for 12.5% of patients, and
≥0.4 CTCs∕ml for 52.5% of patients.
We detected CTCs in 20% of stage III and IV patients. The lower rate of CTC detection
compared to the work of Khoja et al. may be due in part to our utilization of only a single marker
(melanin) rather than three separate markers, as well as the fact that our patients were measured
at only one clinical timepoint instead of on multiple repeat visits. In our study, we detected both
single CTCs and CTC clusters, and we estimate that a cluster of CTCs likely represents two
to four CTC cells, based on the sizes of the clusters in the images. Using this estimate along
with the effective sampled blood volume per patient suggests that ∼0.06 to 0.11 CTCs∕ml
were detected in patent M3, 0.07 CTCs∕ml were detected in patient M11, and 0.15 to
−0.30 CTCs∕ml were detected in patient M14. These estimates are in overall agreement with
the CTC per unit volume reported by Khoja et al.28
Recently, another group also reported in vivo melanoma detection using a photoacoustic
technique,29 with a 96% detection rate and a 94% specificity. The duration of their examinations
was longer than 1 h, in comparison with our 20-min exams. The reported number density of
CTCs29 was consistent with the numbers that we measured from the three CTC-positive patients.
Because both studies were not randomized and had a limited population size, the conclusions
drawn from the two studies must be further examined in large-scale, randomized, and blinded
studies.
It is worth noting that the efficacy of LA-PAT in CTC imaging depends on patient factors.
First, skin pigmentation influences LA-PAT imaging. All 16 patients in the current work were
Caucasians with Fitzpatrick type I-II skin. Indeed, previous studies have found that darkly
pigmented skin absorbs about 30% to 40% more laser energy than lightly pigmented skin.30
This increased absorption would result in a simulation-predicted decrease in the maximum
imaging depth of ∼2.5 mm.31 This depth is not a significant limitation because the epidermis
can vary between 0.05 and 1.5 mm in humans, and therefore dermal blood vessels would still be
accessible to LA-PAT in darker pigmented skin. Furthermore, the risk of melanoma is higher in
lighter skin types than darker skin types,32 suggesting that LA-PATwould be particularly suited
for application to most patients with malignant melanoma.
Second, the types and amounts of pigment produced in melanoma cells depend on genotypes.
For example, amelanotic melanoma, a rare clinical type of melanoma that comprises less
than ∼5% of the total melanoma cases,33–36 produces only a small amount of brown melanin
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(eumelanin). Fortunately, amelanotic melanoma is a rare subtype, so its potential detection
limitation does not significantly limit the broader utility of LA-PAT.
While both the presence of melanin and background pigmentation present potential variables
that may make CTC detection more difficult, a further question is determining whether the
LA-PAT signal is indeed specific for circulating melanoma tumor cells. Our results clearly dem-
onstrate that LA-PAT is capable of detecting flowing melanoma tumor cells in phantom experi-
ments under conditions that are physiologically relevant to human patients. However, the three
patients with detected CTC events may have had detected signals due to benign circulating
melanocytes or melanin-laden macrophages instead of circulating melanoma tumor cells.
Several studies have provided insight into the possible mischaracterization of benign circulating
melanocytes as melanoma cells.33–35 De Giorgi et al. reported the first case of benign nevus cells
being detected in peripheral blood samples from a patient with a benign congenital nevus.33
Though this case demonstrates that a patient without melanoma can have benign circulating
melanocytes, other work has shown that patients with melanoma are more likely to have nevus
cells found in lymph nodes,34,35 suggesting that patients with melanoma may be more likely to
have nevus cells that acquire the ability to migrate outside of the primary cutaneous neoplasm.
Nonetheless, our findings represent an important and nontrivial “proof of concept”—that
melanin-containing cells can be imaged in vivo using LA-PAT, and that this capability has poten-
tial clinical relevance.
To confirm clinical relevance, however, larger, controlled studies are necessary. Future stud-
ies should include imaging CTCs in age-matched nonmelanoma controls and patients with
multiple nevi, as well additional imaging of stages I to IV melanoma patients. Importantly,
ex vivo validation using existing verified platforms for circulating tumor DNA (ctDNA) or
other enriching platforms using tumor markers would be important in verifying that LA-PAT-
determined CTCs are indeed CTCs and not benign melanin-containing cells. Furthermore, the
presence of circulating melanin-containing cells in patients with late stage metastatic melanoma
may be a clinically relevant finding, regardless of whether these cells are tumor cells or not.
We also propose that the functionality of LA-PAT can be further improved. Detection sen-
sitivity can be improved by spectrally unmixing melanoma CTCs and RBCs using two or more
illumination wavelengths.37 Blood screening throughput can be enhanced by targeting larger
blood vessels and optimizing the imaging frame rate to better match the blood flow speed.
Moreover, by applying a second laser pulse with higher energy immediately after identifying
a melanoma CTC, selective laser fragmentation of melanoma CTCs can be achieved. This
fragmentation in turn would theoretically lead to the release of melanoma tumor antigens,
with subsequent presentation to immune cells, which may help instigate an adaptive immune
response.38,39 This hypothesis is particularly attractive in patients whose metastatic tumors are
small or in locations that may not be amenable to other modalities that serve to augment treat-
ment response to immunotherapy, such as radiation or the injection of cytolytic tumor vaccines.
LA-PAT can also be applied to image CTCs in the lymph,40 but the weak optical absorption of
lymph may require labeling in order to locate the lymphatic system. In addition to CTC detec-
tion, LA-PAT can measure other parameters, including depth, pH, oxygen saturation, stiffness,
glucose metabolism, angiogenesis, and therapy response, to provide comprehensive information
about solid tumors and metastasis.41–46
We have previously reported that LA-PAT is a potentially useful tool in the management of
primary melanoma (in vivo determination of melanoma depth),23 and we now present data on its
potential application in the detection and management of metastatic melanoma. We recognize
that, due to the small number of patients imaged in this pilot study and the variable time of follow-
up, the prognostic value of the detection of these circulating cells has not been determined. It is
interesting, however, that the majority of patients without detected suspected CTCs had no dis-
ease progression over the short follow-up period. Larger controlled trials as described above,
with extended clinical follow-up, will be necessary to determine optimal clinical applications.
The label-free and noninvasive nature of LA-PAT imaging of melanoma CTCs presents an
inherent advantage for patients, avoiding the need for specific contrast agents or patient blood
draws. LA-PAT could be an easily employable bedside modality for monitoring disease progres-
sion and response to therapy over time. Furthermore, our method relies on the production of
melanin within melanoma cells, rather than the expression of cell surface receptors, and therefore
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offers an independent noninvasive modality that can complement other methods, such as ex vivo
CTC detection assays that target cell surface receptors.28 Finally, the development of contrast
agents for molecular photoacoustic imaging can extend the capability of LA-PAT to imaging
cancer cells that do not express melanin.47 While future controlled studies with larger patient
populations including ex vivo tumor cell validation are needed to definitively assess the prog-
nostic value of LA-PAT detected CTCs, we believe that this is the first step toward the develop-
ment of a technology that can constantly monitor CTCs in the circulatory system for disease
management.
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